Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Gains from Investment Securities (2017 - 2024)

Selectis Health's Gains from Investment Securities history spans 11 years, with the latest figure at $2.1 million for Q2 2024.

  • For Q2 2024, Gains from Investment Securities changed N/A year-over-year to $2.1 million; the TTM value through Dec 2024 reached $2.1 million, changed N/A, while the annual FY2024 figure was $2.1 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q2 2024 was $2.1 million at Selectis Health, up from $206000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.1 million in Q2 2024 and bottomed at $41000.0 in Q4 2020.
  • The 4-year median for Gains from Investment Securities is $206000.0 (2022), against an average of $603828.6.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 786.29% in 2020 before it plummeted 65.67% in 2022.
  • A 4-year view of Gains from Investment Securities shows it stood at $41000.0 in 2020, then surged by 46.34% to $60000.0 in 2021, then soared by 243.33% to $206000.0 in 2022, then soared by 925.31% to $2.1 million in 2024.
  • Per Business Quant, the three most recent readings for GBCS's Gains from Investment Securities are $2.1 million (Q2 2024), $206000.0 (Q2 2022), and $60000.0 (Q4 2021).